| scholarly article | Q13442814 |
| P356 | DOI | 10.1179/1607845412Y.0000000067 |
| P698 | PubMed publication ID | 23394475 |
| P2093 | author name string | Ahmed M L Bedewy | |
| Shereen M El-Maghraby | |||
| P2860 | cites work | Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 |
| Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans | Q28140931 | ||
| Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). | Q34330241 | ||
| Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet | Q34567629 | ||
| Clinical pharmacokinetics of imatinib | Q36240739 | ||
| Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). | Q36280662 | ||
| Pharmacogenomics of human OATP transporters | Q36416907 | ||
| Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors | Q36612755 | ||
| Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer | Q36974142 | ||
| Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet | Q37163550 | ||
| Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia | Q42933358 | ||
| CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity | Q43200942 | ||
| CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers | Q44675164 | ||
| Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. | Q45936706 | ||
| Inhibition of imatinib transport by uremic toxins during renal failure | Q46403767 | ||
| Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study | Q46767695 | ||
| Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression | Q46906576 | ||
| Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. | Q50641149 | ||
| Genetic polymorphism of CYP3A5 in Indian chronic myeloid leukemia patients. | Q53366009 | ||
| Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. | Q54601398 | ||
| P433 | issue | 4 | |
| P921 | main subject | imatinib | Q177094 |
| chronic myeloid leukemia | Q729735 | ||
| P304 | page(s) | 211-216 | |
| P577 | publication date | 2013-01-31 | |
| P1433 | published in | Hematology | Q15752084 |
| P1476 | title | Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy? | |
| P478 | volume | 18 |
| Q99711975 | Association of the Trough, Peak/Trough Ratio of Imatinib, Pyridine-N-Oxide Imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G With Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients |
| Q87230149 | Genetic polymorphisms in cytochrome P450 and clinical outcomes of FOLFIRI chemotherapy in patients with metastatic colorectal cancer |
| Q53803475 | Impact of CYP3A4*18 and CYP3A5*3 Polymorphisms on Imatinib Mesylate Response Among Chronic Myeloid Leukemia Patients in Malaysia. |
| Q50261890 | Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia. |
| Q38996487 | Pharmacogenetics of drug transporters in modulating imatinib disposition and treatment outcomes in chronic myeloid leukemia & gastrointestinal stromal tumor patients |
| Q58588447 | The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients |
| Q37663396 | Uptake carriers and oncology drug safety |
Search more.